These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 2502639

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Synergism of tissue-type plasminogen activator (t-PA) and single-chain urokinase-type plasminogen activator (scu-PA) on clot lysis in vitro and a mechanism for this effect.
    Gurewich V, Pannell R.
    Thromb Haemost; 1987 Jun 03; 57(3):372-3. PubMed ID: 3116707
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Characterization of the intrinsic fibrinolytic properties of pro-urokinase through a study of plasmin-resistant mutant forms produced by site-specific mutagenesis of lysine(158).
    Gurewich V, Pannell R, Broeze RJ, Mao J.
    J Clin Invest; 1988 Dec 03; 82(6):1956-62. PubMed ID: 2974047
    [Abstract] [Full Text] [Related]

  • 25. The role of the fibrinolytic system in corneal angiogenesis.
    Vogten JM, Reijerkerk A, Meijers JC, Voest EE, Borel Rinkes IH, Gebbink MF.
    Angiogenesis; 2003 Dec 03; 6(4):311-6. PubMed ID: 15166500
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [The fibrinolytic system and its activators].
    Seifried E.
    Z Gesamte Inn Med; 1993 Dec 03; 48(6-7):272-82. PubMed ID: 8333223
    [Abstract] [Full Text] [Related]

  • 28. Fibrinolysis--a review.
    Kane KK.
    Ann Clin Lab Sci; 1984 Dec 03; 14(6):443-9. PubMed ID: 6239587
    [Abstract] [Full Text] [Related]

  • 29. Physiological consequences of loss of plasminogen activator gene function in mice.
    Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, De Vos R, van den Oord JJ, Collen D, Mulligan RC.
    Nature; 1994 Mar 31; 368(6470):419-24. PubMed ID: 8133887
    [Abstract] [Full Text] [Related]

  • 30. [Fibrinolytic therapy].
    Beyer J, Schellong S.
    Hamostaseologie; 2005 Nov 31; 25(4):345-55. PubMed ID: 16395484
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. [Molecular mechanisms of fibrinolysis and perspectives of thrombolytic therapy].
    Veremeenko KN, Kizim AI.
    Vopr Med Khim; 1984 Nov 31; 30(5):13-22. PubMed ID: 6084892
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.